Post-Bariatric Hypoglycemia Epidemiology

Post Bariatric Hypoglycemia (PBH) Insights and Trends

• According to DelveInsight’s analysis, the total prevalent cases of PBH were ~ 744,700 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• PBH is a chronic metabolic complication following bariatric surgery, characterized by recurrent postprandial hypoglycemia caused by exaggerated insulin secretion. The condition is increasingly recognized due to the rising global adoption of bariatric procedures and the growing long-term post-surgical population. PBH is mainly associated with Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy, with RYGB linked to higher hypoglycemia risk and sleeve gastrectomy contributing a larger overall patient burden due to higher procedural volume.
• Females account for the majority of PBH cases globally, largely reflecting the disproportionately higher utilization of bariatric surgery among women. Hormonal influences, pregnancy-related weight retention, PCOS-associated metabolic dysfunction, and greater healthcare-seeking behavior contribute to the higher surgical uptake and consequently greater PBH burden in females.
• Diagnosis of PBH remains highly challenging due to the absence of universally accepted diagnostic criteria and the overlap of symptoms with dumping syndrome, anxiety disorders, insulinoma, and other metabolic conditions. Many patients remain underdiagnosed or misdiagnosed, leading to delays in treatment initiation and long-term disease management.
• Continuous glucose monitoring (CGM), mixed-meal tolerance testing (MMTT), symptom evaluation, and confirmation of Whipple’s triad remain the major approaches used for PBH diagnosis. Among these, CGM has gained increasing clinical importance due to its ability to detect asymptomatic and nocturnal hypoglycemic episodes that are often missed in routine assessments.
• The burden of PBH is expected to continue rising despite declining bariatric surgery volumes in some markets due to increased use of anti-obesity drugs. A growing population of post-surgical patients, ongoing procedures in regions such as Europe, and the accumulation of both existing and new cases are projected to steadily expand the overall PBH patient pool over time.

Post Bariatric Hypoglycemia (PBH) Epidemiology Forecast in 7MM

• 2025 Prevalent Cases of PBH: ~ 744,700
• 2036 Projected Prevalent Cases of PBH: XXXX
• PBH Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Post Bariatric Hypoglycemia (PBH)– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the PBH, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Post Bariatric Hypoglycemia (PBH) Understanding and Diagnosis Algorithm

PBH is a complication that occurs after bariatric surgeries such as Roux-en-Y gastric bypass or sleeve gastrectomy. It is characterized by low blood glucose levels, typically 1–3 hours after meals. PBH results from rapid nutrient absorption and an exaggerated insulin response, largely driven by increased GLP-1 secretion. Patients may experience symptoms such as dizziness, sweating, and confusion, with severity ranging from mild to severe. Management mainly involves dietary changes, with medications or surgical intervention required in severe cases.

PBH is diagnosed based on clinical symptoms and confirmation of Whipple’s triad, low blood glucose, associated symptoms, and symptom relief after glucose intake. A MMTT is the preferred method to assess postprandial hypoglycemia, while CGM helps detect recurrent episodes. Additional tests may be used to confirm hyperinsulinemia and exclude conditions such as insulinoma.

Further details are provided in the report.

Post Bariatric Hypoglycemia (PBH) Epidemiology

Key Findings from PBH Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, the total number of prevalent cases of PBH in the 7MM was nearly 744,700 cases in 2025 and is projected to increase during the forecasted period.
• The total number of prevalent cases of PBH in the United States was nearly 428,500 in 2025.
• Among the EU4, France accounted for the highest number of prevalent cases of PBH, followed by Germany, whereas Italy accounted for the lowest number of cases in 2025.
• Across the 7MM, the prevalence of PBH is highest among patients undergoing RYGB, followed by sleeve gastrectomy, while other bariatric surgery procedures account for the lowest prevalence of PBH.
• The observed female predominance and earlier onset of PBH highlight the importance of early postoperative monitoring, timely diagnosis, individualized nutritional management, and targeted therapeutic interventions to reduce hypoglycemic complications and improve long-term patient outcomes.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of PBH, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• PBH patient population forecast

Report Key Strengths

• Epidemiology-based (epi-based) bottom-up forecasting
• 11-year forecast
• Patient burden trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of PBH? What will be the growth opportunities across the 7MM concerning the patient population with PBH?
• What is the historical and forecasted PBH patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.